Evotec (NASDAQ:EVO) Shares Gap Up - Here's What Happened

Key Points

• Evotec shares opened higher at $2.10 versus a prior close of $2.00, and last traded near $2.0950 on modest volume.
• Analyst sentiment is mixed but leans cautious: the stock carries a consensus “Hold” rating and a $3.00 average price target, with several firms recently downgrading their views.
• Institutional ownership stands at 5.81%, while recent investors including Bank of America and BNP Paribas increased their positions. Evotec is a Germany-based biotechnology company focused on drug discovery and development partnerships.

Evotec AG (NASDAQ:EVO - Get Free Report)'s stock price gapped up before the market opened on Monday . The stock had previously closed at $2.00, but opened at $2.10. Evotec shares last traded at $2.0950, with a volume of 14,548 shares traded.

Analyst Upgrades and Downgrades

EVO has been the topic of several recent research reports. Weiss Ratings reiterated a "sell (d-)" rating on shares of Evotec in a research report on Tuesday, July 21st. TD Cowen downgraded Evotec from a "buy" rating to a "hold" rating and set a $2.00 price objective on the stock. in a report on Wednesday, July 15th. Wall Street Zen lowered Evotec from a "hold" rating to a "sell" rating in a research note on Saturday, May 9th. Berenberg Bank cut Evotec from a "buy" rating to a "hold" rating in a report on Thursday, July 16th. Finally, HC Wainwright cut their target price on Evotec from $7.00 to $4.00 and set a "buy" rating for the company in a research report on Wednesday, July 15th. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $3.00.

Evotec Stock Performance

The company has a quick ratio of 1.60, a current ratio of 1.68 and a debt-to-equity ratio of 0.43. The company's fifty day moving average price is $2.46 and its two-hundred day moving average price is $2.85.

Institutional Trading of Evotec

Large investors have recently added to or reduced their stakes in the company. XTX Topco Ltd raised its position in Evotec by 25.1% in the 4th quarter. XTX Topco Ltd now owns 18,469 shares of the company's stock valued at $57,000 after purchasing an additional 3,709 shares during the last quarter. BNP Paribas Financial Markets grew its holdings in shares of Evotec by 62.2% during the second quarter. BNP Paribas Financial Markets now owns 12,000 shares of the company's stock worth $50,000 after purchasing an additional 4,600 shares during the last quarter. Bank of America Corp DE grew its holdings in shares of Evotec by 262.5% during the fourth quarter. Bank of America Corp DE now owns 12,828 shares of the company's stock worth $53,000 after purchasing an additional 9,289 shares during the last quarter. Apollon Wealth Management LLC acquired a new stake in shares of Evotec in the first quarter valued at $28,000. Finally, Marshall Wace LLP bought a new position in shares of Evotec in the fourth quarter valued at about $40,000. 5.81% of the stock is owned by institutional investors.

About Evotec

Evotec SE NASDAQ: EVO is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec's service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source